Dr. Hung's research focuses on developing vaccination strategies for the prevention and treatment of cervical and ovarian cancers.
His lab has developed several approaches to enhance immunologic responses against different cancers. Some of these involve
- targeting antigen into dendritic cells (DCs),
- targeting antigen into major histocompatability class I and II processing pathways,
- enhancing intercellular spreading of antigen, and
- combining antigen-specific immunotherapy with agents to limit angiogenesis.
Dr. Hung's research has led to the generation of clinical-grade vaccines for HPV-associated precancerous and cancerous lesions. Of special note, two of Dr. Hung's technologies (DNA vaccines based on HSP70 and calreticulin fusion technologies) have also been licensed and are under active development by biotechnology companies. Recently, Dr. Hung's lab has utilized annexin V (AnnV) as an immune checkpoint inhibitor and tumor-homing molecule for the treatment of cancer, as AnnV greatly enhances the immunogenicity and antitumor efficacy after chemoradiation.
Additionally, Dr. Hung has developed a novel universal immunotherapeutic molecule (Alb-Flt3L) by harnessing albumin's ability to extend serum half-life and preferential trafficking towards lymph nodes as well as the properties of Flt3L to potently expand cross-presenting DCs. Alb-Flt3L enhances immunological responses mediated by cross-presenting DCs and subsequently generates potent antigen-specific T and B cell responses.
Yang, A, Jeang, J, Cheng, K, Cheng, T, Yang, B, Wu, TC, and Hung, CF. Current State in the Development of Candidate Therapeutic HPV Vaccines. Expert Rev Vaccines 2016; 15(8):989-1007.
Soong, RS., Anchoori R, Yang B, Yang A, Tseng SH, He L, Tsai YC, Roden RB, and Hung CF. RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells. Oncotarget 2016; 7, 68489-68502
Hung CF, Xu X, Li L, Ma Y, Jin Q, Viley A, Allen C, Natarajan P, Shivakumar R, Peshwa MV and Emens LA. Development of Anti-Human Mesothelin-Targeted Chimeric Antigen Receptor Messenger RNA-Transfected Peripheral Blood Lymphocytes for Ovarian Cancer Therapy. Hum Gene Ther. 2018; 29:614-625
Kang TH, Park JH, Yang A, Park HJ, Lee SE, Kim YS, Jang GY, Farmer, E, Park YM, Hung CF. AnnexinV as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment. (under revision in Nature Communications)
Lam B, Tseng SH, Cheng MA, Farmer E, Hung CF. The role of Albumin-Flt3L-induced cross-presenting dendritic cell expansion in antitumor immunity. (manuscript in preparation)